Navigation Links
Poniard Pharmaceuticals Announces Updated Positive Clinical Data from Phase 2 Trial of Picoplatin in Colorectal Cancer and New Phase 1 Cardiac Safety Trial Results
Date:11/17/2009

SOUTH SAN FRANCISCO, Calif., Nov. 17 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD) today announced updated clinical data from its randomized, controlled Phase 2 trial of picoplatin in patients with metastatic colorectal cancer (CRC). The updated results indicated that picoplatin, given once every four weeks in combination with 5-fluorouracil and leucovorin in the FOLPI regimen, has comparable efficacy to oxaliplatin, given in combination with 5-fluorouracil and leucovorin in the modified FOLFOX-6 regimen, as a first-line therapy for CRC, as assessed by one-year survival rate, progression-free survival (PFS) and disease control. The Company also announced new results from its Phase 1 cardiac safety trial, which showed no clinical cardiac-related events, as expected.

New data for both clinical trials were presented today in poster sessions during the AACR-NCI-EORTC's "Molecular Targets and Cancer Therapeutics" International Conference in Boston. Picoplatin is a new generation platinum-based chemotherapy agent and the Company's lead product candidate in development.

"Our updated proof-of-concept Phase 2 safety and efficacy results continue to suggest that picoplatin could be superior to oxaliplatin as a neuropathy-sparing alternative when used in combination as a first-line treatment for metastatic colorectal cancer. We are continuing follow-up on patients to obtain median overall survival data to facilitate an end of Phase 2 meeting with the U.S. Food and Drug Administration," said Jerry McMahon, Ph.D., chairman and CEO of Poniard. "Based on the current data in colorectal cancer, as well as encouraging efficacy and safety data from more than 1,100 cancer patients treated with picoplatin in clinical trials, including the cardiac safety trial data presented today, we are continuing discussions wi
'/>"/>

SOURCE Poniard Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Poniard Pharmaceuticals to Present Updated Results of Picoplatin Phase 2 Small Cell Lung Cancer Trial at 12th World Conference on Lung Cancer
2. Poniard Pharmaceuticals Announces Updated Results of Picoplatin Phase 2 Trial Demonstrating Survival Benefit in Small Cell Lung Cancer Patients
3. Poniard Pharmaceuticals Receives FDA Fast Track Designation for Picoplatin for Treatment of Small Cell Lung Cancer
4. Poniard Pharmaceuticals Initiates Randomized Phase 2 Trial of Picoplatin for First-Line Treatment of Metastatic Colorectal Cancer
5. Poniard Pharmaceuticals Provides Year-End Clinical Update at 2007 Lazard Capital Markets Healthcare Conference
6. Poniard Pharmaceuticals Announces Picoplatin Safety Data in Colorectal Cancer
7. Poniard Pharmaceuticals Announces Positive First-line Phase 1 Safety and Efficacy Data With Picoplatin in Metastatic Prostate Cancer Patients
8. Poniard Pharmaceuticals Announces Clinical Data From Picoplatin Oral Phase 1 to Be Presented at the American Association of Cancer Research Annual Meeting
9. Poniard Pharmaceuticals Announces Commercial Manufacturing Agreement With W. C. Heraeus GmbH for Picoplatin
10. Poniard Pharmaceuticals Announces Presentation of Clinical Data From Picoplatin Phase 2 Small Cell Lung Cancer Trial to be Presented at 1st IASLC-ESMO European Lung Cancer Conference
11. Poniard Pharmaceuticals Oral Picoplatin Demonstrates Positive Bioavailability in Ongoing Phase 1 Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... -- The spinal column is one of the most delicate ... and from the brain through the column control many key ... ailment here can be life altering, and leave the victim ... their body. Though back injury and disease can have an ... options available to make things better than ever before. ...
(Date:8/21/2014)... 2014  Decision Resources Group finds that, for ... Brazil and Mexico ... prescribe long-acting beta-agonist (LABA)- and long-acting muscarinic antagonist ... current severe cost/coverage constraints. Therefore, new brands of ... launch in these countries—which will considerably expand the ...
(Date:8/21/2014)... -- Seventy-one percent of Americans believe the abuse of strong prescription ... and safety issue in the United States ... Repass & Partners, a Cincinnati based ... of the prescription medication abuse problem and the need for ... situation facing our country," Rex Repass , CEO of ...
Breaking Medicine Technology:Don't Live in Pain: Four Life Improving Benefits of Back Surgery 2Novel Fixed-Dose Combinations for COPD in Brazil and Mexico Will Compete With Well-Established Therapies in an Environment Dominated by Aggressive Cost-Control Mechanisms 2Novel Fixed-Dose Combinations for COPD in Brazil and Mexico Will Compete With Well-Established Therapies in an Environment Dominated by Aggressive Cost-Control Mechanisms 3Consumers Desperate For Measures To Curb Prescription Drug Abuse 2Consumers Desperate For Measures To Curb Prescription Drug Abuse 3
... announces that a new market research report is ... RNAi Drug Delivery: Technologies and Global Markets ... THIS REPORT CONTAINS An ... technologies market is applied in therapeutics, research and ...
... China, March 23, 2011 /PRNewswire-Asia/ -- China Medicine Corporation ... a leading manufacturer, developer and distributor of Western pharmaceuticals, ... the People,s Republic of China, today announced that it ... Commission 1) a Current Report on Form 8-K to ...
Cached Medicine Technology:Reportlinker Adds RNAi Drug Delivery: Technologies and Global Markets 2Reportlinker Adds RNAi Drug Delivery: Technologies and Global Markets 3Reportlinker Adds RNAi Drug Delivery: Technologies and Global Markets 4Reportlinker Adds RNAi Drug Delivery: Technologies and Global Markets 5Reportlinker Adds RNAi Drug Delivery: Technologies and Global Markets 6Reportlinker Adds RNAi Drug Delivery: Technologies and Global Markets 7Reportlinker Adds RNAi Drug Delivery: Technologies and Global Markets 8Reportlinker Adds RNAi Drug Delivery: Technologies and Global Markets 9Reportlinker Adds RNAi Drug Delivery: Technologies and Global Markets 10Reportlinker Adds RNAi Drug Delivery: Technologies and Global Markets 11Reportlinker Adds RNAi Drug Delivery: Technologies and Global Markets 12Reportlinker Adds RNAi Drug Delivery: Technologies and Global Markets 13Reportlinker Adds RNAi Drug Delivery: Technologies and Global Markets 14China Medicine Corporation Files Extension for Fiscal 2010 Form 10-K Filing 2China Medicine Corporation Files Extension for Fiscal 2010 Form 10-K Filing 3
(Date:8/22/2014)... (PRWEB) August 22, 2014 Home ... of in-home care for seniors, is proud to announce ... Series. The upcoming webinar will feature Dr. Suzanne Steinbaum, ... Lenox Hill Hospital in New York City, National Spokesperson ... author. The webinar will cover the issues surrounding women ...
(Date:8/22/2014)... 22, 2014 (HealthDay News) -- Counseling may do little ... review finds. Researchers analyzed 66 studies that included ... were at high risk for drinking problems. Participants in ... participants in the rest of the studies attended group ... A counseling technique called motivational interviewing was used ...
(Date:8/22/2014)... 2014 (HealthDay News) -- Inner city children have a higher-than-normal ... Researchers followed 516 inner city children in four U.S. cities ... birth until age 5 and found that at least 10 ... peanuts. Because only the three most common types of ... of inner city youngsters with food allergies may be even ...
(Date:8/22/2014)... few years, several breakthrough treatments have become available ... may benefit from these treatments can be pre-identified ... cancer. For example, patients whose lung cancer is ... significant benefit from the drug crizotinib, which targets ... attempting to replicate this success by matching different ...
(Date:8/22/2014)... severe disabilities and multiple chronic conditions are screened for ... or no chronic conditions, a new study has found. ... with moderate disabilities or women with only one chronic ... with the Li Ka Shing Knowledge Institute of St. ... often have other measures of social vulnerability, such as ...
Breaking Medicine News(10 mins):Health News:Home Care Assistance of Centennial to Host Webinar on Heart Health, Featuring Dr. Suzanne Steinbaum 2Health News:Home Care Assistance of Centennial to Host Webinar on Heart Health, Featuring Dr. Suzanne Steinbaum 3Health News:Counseling Does Little to Deter Youth Drinking, Review Finds 2Health News:Food Allergies More Common Among Inner City Kids, Study Finds 2Health News:Online screening for rare lung cancer subtypes opens door to new kind of clinical trial 2Health News:Online screening for rare lung cancer subtypes opens door to new kind of clinical trial 3Health News:Online screening for rare lung cancer subtypes opens door to new kind of clinical trial 4Health News:Women with severe, chronic health issues are screened for breast cancer less often 2
... , TUESDAY, Aug. 16 (HealthDay News) -- For some ... of the disease who find standard treatments either intolerable ... relief. A new injectable treatment called pegloticase (brand ... patients, but researchers say that for the roughly ...
... Pneumonia kills more children around the world than any ... the causes of childhood pneumonia across many countries was ... study called the Pneumonia Etiology Research for Child Health ... 5 African and 2 Asian research sites coordinated by ...
... was a dramatic increase in the number of children,s flu-related hospital ... agency says. Over that time, flu rose from 65th to ... younger go to the hospital, according to a report from the ... found that skin infections rose from 13th to 7th in the ...
... Foundation launched a major new collaboration created with ... with its announcement that it will provide funding ... interventional radiology during 2012󈝹 in the Howard Hughes ... "The SIR Foundation, which seeks to further ...
... new study has shown the Flexible-Fiber CO2 laser to ... (TSC) without the,line of sight problems encountered with conventional ... Medical Center (BMC) and Boston University School of Medicine ... Neurosurgery . This is the first study to report ...
... for 15 minutes a day, or 92 minutes per week, ... who are inactive, according to a study published today in ... reduced deaths from any cause by 14 percent," said study ... The University of Texas MD Anderson Cancer Center Department of ...
Cached Medicine News:Health News:New Drug May Relieve Severe, Tough-to-Treat Gout 2Health News:New Drug May Relieve Severe, Tough-to-Treat Gout 3Health News:New Drug May Relieve Severe, Tough-to-Treat Gout 4Health News:Largest global childhood pneumonia etiology study launched 2Health News:Largest global childhood pneumonia etiology study launched 3Health News:Society of Interventional Radiology Foundation funds Howard Hughes Medical Institute Award 2Health News:Study finds flexible-fiber CO2 laser safe in endoscopic endonasal transsphenoidal surgery 2Health News:Study finds 15 minutes of moderate daily exercise lengthens life 2Health News:Study finds 15 minutes of moderate daily exercise lengthens life 3
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: